secwatch.observer — SEC 8-K summary
======================================

Issuer:     MBX Biosciences, Inc. (MBX)
CIK:        0001776111
Form:       8-K
Filed at:   2025-09-22T23:59:59+00:00
Accession:  0001193125-25-210049
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MBX Biosciences' canvuparatide meets Phase 2 primary endpoint: 63% responder rate, p=0.042, 79% at 6 months OLE
--------------------------------------------------------------------------------

- Primary composite endpoint met: 63% (30/48) of canvuparatide patients vs 31% (5/16) placebo at Week 12 (p=0.042).
- Open-label extension: 79% (44/56) achieved responder status at 6 months, including placebo crossovers.
- Safety: well-tolerated, no treatment-related SAEs or discontinuations; injection site reactions 19% vs 13% placebo.
- Company plans to initiate Phase 3 trial of once-weekly canvuparatide in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1776111/000119312525210049/0001193125-25-210049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1776111/000119312525210049/mbx-20250922.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-210049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer